All In Biotech

Drug Trial Radar · NCT00812461

Efficacy of Nalmefene in Patients With Alcohol Dependence

Nalmefene Efficacy Study II: Randomised, Double-blind, Placebo-controlled, Parallel-group, Efficacy Study of 20 mg Nalmefene, as Needed Use, in Patients With Alcohol Dependence

Last checked: Nov 20, 2026Latest source record: Jul 22, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 678 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

678

Actual

Start

Mar 2009

Primary completion

Mar 2011

Study completion Apr 2011

Sponsor

Lead sponsor
H. Lundbeck A/SIndustry
Sponsor type
Industry
First posted
Dec 22, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate the efficacy, safety and tolerability of nalmefene in the treatment of alcohol dependence.

Conditions

  • Alcohol Dependence

Interventions

  • PlaceboDrug

    as-needed use, tablets, orally, 6 months

  • NalmefeneDrug

    18.06 mg, as-needed use, tablets, orally, 6 months. 18.06 mg nalmefene equals 20 mg nalmefene hydrochloride.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in the Monthly Number of Heavy Drinking Days (HDDs)Time frame: Baseline and Month 6
  2. Change From Baseline in the Monthly Total Alcohol Consumption (TAC)Time frame: Baseline and Month 6

Locations

57 sites in 7 countries. Site status is shown where the registry gives one.

  • BE002

    Assebroek, Belgium

  • BE007

    Bruges, Belgium

  • BE006

    Charleroi, Belgium

  • BE005

    Kortenberg, Belgium

  • BE001

    Liège, Belgium

  • BE003

    Mechelen, Belgium

  • BE004

    Ostend, Belgium

  • CZ001

    Litoměřice, Czechia

  • CZ002

    Prague, Czechia

  • CZ003

    Prague, Czechia

  • FR008

    Angers, France

  • FR004

    Bully-les-Mines, France

  • FR009

    Clichy, France

  • FR012

    Élancourt, France

  • FR021

    La Rochelle, France

  • FR011

    Le Pecq, France

  • FR019

    Lille, France

  • FR016

    Lyon, France

  • FR014

    Nancy, France

  • FR015

    Nîmes, France

  • FR002

    Rennes, France

  • FR001

    Sartrouville, France

  • FR007

    Strasbourg, France

  • FR005

    Toulouse, France

  • FR006

    Toulouse, France

  • FR003

    Villejuif, France

  • IT017

    Bologna, Italy

  • IT013

    Bologna, Italy

  • IT008

    Cento, Italy

  • IT006

    Florence, Italy

  • IT002

    Parma, Italy

  • IT007

    Rome, Italy

  • IT001

    Rome, Italy

  • IT011

    Rome, Italy

  • IT004

    Rome, Italy

  • IT018

    Soverato Marina, Italy

  • PL005

    Gdansk, Poland

  • PL004

    Leszno, Poland

  • PL006

    Lublin, Poland

  • PL007

    Lublin, Poland

Showing 40 of 57 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.